Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Net Income towards Common Stockholders (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Net Income towards Common Stockholders for 16 consecutive years, with $3.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income towards Common Stockholders rose 221.17% to $3.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.7 million, a 109.57% increase, with the full-year FY2024 number at $12.1 million, up 114.14% from a year prior.
  • Net Income towards Common Stockholders was $3.6 million for Q3 2025 at Gyre Therapeutics, up from $442000.0 in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $51.6 million in Q2 2022 to a low of -$81.7 million in Q4 2023.
  • A 5-year average of -$7.7 million and a median of -$99000.0 in 2024 define the central range for Net Income towards Common Stockholders.
  • Peak YoY movement for Net Income towards Common Stockholders: crashed 453.61% in 2021, then skyrocketed 359.09% in 2022.
  • Gyre Therapeutics' Net Income towards Common Stockholders stood at -$20.4 million in 2021, then crashed by 46.71% to -$29.9 million in 2022, then crashed by 173.13% to -$81.7 million in 2023, then skyrocketed by 99.88% to -$99000.0 in 2024, then soared by 3746.46% to $3.6 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Net Income towards Common Stockholders are $3.6 million (Q3 2025), $442000.0 (Q2 2025), and $2.7 million (Q1 2025).